Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06928246
PHASE1

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Sponsor: Daniel Kaplan

View on ClinicalTrials.gov

Summary

The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.

Official title: Pilot Study on Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

8

Start Date

2025-07-17

Completion Date

2027-01

Last Updated

2026-02-03

Healthy Volunteers

No

Interventions

DRUG

Onabotulinum Toxin Type A - Phase 1b

The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 50 units per patient.

DRUG

Onabotulinum Toxin Type A - Phase 2

The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 75 units per patient.

Locations (2)

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

UPMC Department of Dermatology

Pittsburgh, Pennsylvania, United States